A Phase 2 Clinical Trial Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of PRAX-944 in Adults with Essential Tremor
Latest Information Update: 06 Mar 2024
At a glance
- Drugs Ulixacaltamide (Primary)
- Indications Essential tremor
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Praxis Precision Medicines
- 18 Sep 2022 Results (n=7) presented at the 26th International Congress of Parkinson's Disease and Movement Disorders
- 09 May 2022 Results presented in Praxis Precision Medicines Media Release.
- 26 Apr 2022 preliminary Results from part A(n=7),presented at the 74th Annual Meeting of the American Academy of Neurology 2022